Compare Hinge Health Inc. Class A Common Stock (HNGE) vs D Wave Quantum Inc (QBTS) Price & Performance

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

QBTS (D-Wave Quantum Inc.) trades at $13.38, down 2.62% on the day, reflecting a bearish technical trend amid negative earnings and high valuation metrics. The company reported a net loss of $355.06M on $24.59M revenue for 2025, with a net income margin of -2,001.59%. Recent news highlights ongoing fraud investigations by multiple law firms, though the company continues to advance its quantum computing technology, such as the launch of a gate-model simulator beta program.

The stock presents a high-risk, speculative opportunity with a unanimous analyst buy rating and a consensus price target of $34.38, implying significant upside. However, substantial financial losses, negative cash flow from operations, and legal uncertainties pose severe risks. Investors should weigh the long-term potential of quantum computing against immediate financial instability and litigation overhangs.